SCHEMBL6682735

SCHEMBL6682735

Cc1c2n(c(=O)n(Cc3ccc(C#N)cc3)c1=O)C=C(C(=O)OCc1ccc(F)cc1)NC2

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.38
HTT P42858 2/20 0.38
LMNA P02545 2/20 0.38
RIPK3 Q9Y572 1/20 0.38
MAPK14 Q16539 1/20 0.37
ALDH1A1 P00352 4/20 0.36
HSD17B10 Q99714 1/20 0.36
FNTA P49354 1/20 0.36
FNTB P49356 1/20 0.36
PGGT1B P53609 1/20 0.36
TSHR P16473 2/20 0.35
MAPT P10636 3/20 0.35
TDP1 Q9NUW8 1/20 0.35
RAB9A P51151 3/20 0.35
MITF O75030 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPC1 O15118 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6683316 0.85 TRPA1 (0.44) KDM4EHTTLMNARIPK3ALDH1A1
SCHEMBL6682041 0.83 MAPK14 (0.39) KDM4EHTTLMNARIPK3MAPK14
SCHEMBL6679886 0.83 KDM4E (0.38) KDM4EHTTLMNARIPK3MAPK14
SCHEMBL6679412 0.71 TRPA1 (0.44) KDM4EHTTALDH1A1HSD17B10MAPT
SCHEMBL6684363 0.71 TRPA1 (0.46) KDM4EHTTLMNAALDH1A1MAPT
SCHEMBL7122539 0.69 KDM4E (0.40) KDM4EHTTLMNAMAPK14ALDH1A1
SCHEMBL6681574 0.69 ALDH1A1 (0.36) KDM4EHTTLMNAMAPK14ALDH1A1
SCHEMBL6679240 0.69 TP53 (0.36) KDM4ELMNAALDH1A1TSHRMAPT
SCHEMBL6681822 0.68 KDM4E (0.40) KDM4EHTTLMNAMAPK14ALDH1A1
SCHEMBL7123266 0.67 KDM4E (0.39) KDM4EHTTLMNAMAPK14ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004014354-A1 1,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed
US-20040034009-A1 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034009-A1 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP11 KDM4E 1434/4885HTT 3183/4885LMNA 3842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.